A Study Testing the Elana Device for Multi-Artery Heart Bypass Surgery

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAMT Medical BV

About this trial

The purpose of the trial is to evaluate the feasibility and safety of multiple Elana Anastomotic Systems to anastomose multiple arterial grafts during coronary artery bypass grafting (CABG). In the first trial performed with the Elana Anastomotic System, the SAFE-CAB trial, only a single anastomosis with the left internal mammary artery (LIMA) was created with the system to the left anterior descending (LAD) coronary artery or a large Diagonal side-branch of the LAD. This is the most important bypass for patients, often described as the anastomosis that guarantees the survival of patients.

However, often multiple anastomoses need to be created during bypass surgery. In the previous study, those anastomoses were performed using vein grafts with standard-of-care hand-sewn techniques. A large body of evidence exists indicating that arterial grafts provide better long-term outcomes for patients undergoing CABG procedures, mainly using the right internal mammary artery (RIMA), but also the Radial Artery, for anastomosis to the Circumflex (Cx) artery and sometimes the Right Coronary Artery. With assurance of safety and effectiveness of the Elena Anastomotic System for LIMA-to-LAD anastomoses and the similarity of the LIMA-to-LAD anastomosis to other arterial anastomoses (e.g., RIMA-to-Cx and RA-to-RCA) as a result of similar vessel diameters and anatomical features, the Elana Anastomotic System is considered to be suitable for multi-arterial bypass procedures.

Therefore, this study aims to expand on the evidence of using the Elana Anastomotic System in a more complete multi-arterial CABG operation, where two or three anastomoses will be created with the Elana Anastomotic System in order to present a more comprehensive solution.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Able and willing to provide voluntary written Informed Consent and sign the Informed Consent Form to participate in the study prior to any study-related procedure,

Is 18 years or older,

Assigned for CABG by the cardiologist and/or cardiothoracic surgeon with one or more vessel disease requiring multiple distal anastomoses, including one on the left anterior descending coronary artery (LAD),

Agrees to attend all follow-up assessments for up to 2 years and is willing to comply with specified follow-up evaluations at clinical investigational sites and/or obtain all protocol-specified diagnostic tests.

Disqualifiers

Patient is unlikely to cooperate or is legally incompetent, including patients who are institutionalized by court or official order,

Any condition which could interfere with the patient's ability to comply with the study,

Ongoing participation in any other interventional clinical study,

Female patients who are pregnant or lactating,

Trial design

Design model

Single group

Treatments tested in this trial

  • The Elana Anastomotic System

    Device

    The Elana Anastomotic System is a medical device and is intended to create a suture less blood vessel anastomosis in Coronary Artery Bypass Grafting (CABG) procedures on the beating heart, without blo

Treatment groups

25 Participants
are divided into 1 treatment group
Group A: Patients will receive two or three bypasses using the Elana Anastomotic System.Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

The primary safety endpoint is defined as the proportion of patients free from all Major Adverse Cardiac Events (MACEs)

MACE is a composite safety parameter that includes the following events: * Cardiac-related mortality, * Myocardial Infarction (in the vessel anastomosed with the Elana Anastomotic System) * Repeated clinically-driven target-vessel coronary revascularization (in the vessel anastomosed with the Elana Anastomotic System).

Time frame
Collected 1 year (365 days) after the surgery

Secondary outcomes

1

The secondary effectiveness endpoint is defined as the graft patency for the ELANA graft/anastomosis.

Graft patency for the ELANA graft/anastomosis will be determined for each ELANA anastomosis separately with coronary angiography (CAG) or coronary computed tomography angiography (CCTA), preferably a photon-counting CT (PCCT).

Time frame
Performed half an year after the surgery (180 days)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: